Indian pharmaceutical stocks, including Lupin, Shilpa Medicare, and Natco Pharma, are under scrutiny following recent USFDA inspections at their manufacturing sites. These audits yielded regulatory observations, prompting companies to address the findings. Alkem Laboratories, however, reported no critical issues from a separate Armenian health ministry audit at its Sikkim facility. Source link India News Several Flights Cancelled As… BNP Paribas adds a Navratna to its… Twitter's India policy head… 49-year-old Chinese citizen… Stock Market Would You Qualify for the Proposed… Active vs. Passive ETF Flows,… Judge dismisses James Comey and… Chinese banks sell off real estate… Space News Rocket…